CEDRUS INVESTMENTS’ CHAIRMAN MR. RANI JARKAS IS INVITED TO SPEAK AT THE HONG KONG BIOTECH INVEST AND PARTNERING 2018

HONG KONG, 13th February, 2018 – The Chairman of Cedrus Investments (“Cedrus”), Mr. Rani Jarkas, is invited as the keynote speaker at the Asian Investment Series of the Hong Kong Biotech Invest & Partnering 2018 conference to be held on 13th March 2018 in Hong Kong. Cedrus has been participating and speaking at this annual event in Hong Kong organized by AusBiotech (Australia’s biotechnology organization) since its inception in 2013 to foster investments in the life sciences industry across borders. In recent years, the Asian Investment Series have expanded further to holding an annual conference in Shanghai which is one of the hubs of life sciences investments in Asia. These conferences have brought together hundreds of Australian life sciences companies together with Hong Kong and Chinese life sciences investors where opportunities of cross-border collaborations are explored, for instance, to tap into the world’s second-largest biopharma market – China.

Mr. Rani Jarkas will be sharing his extensive experience and profound insights, as well as Cedrus’ expertise in life sciences investment and explaining why overseas life sciences companies should be using Hong Kong as the gateway for establishing their presence in Mainland China through joint ventures, licensing partnerships, strategic alliances or other initiatives onshore.

Mr. Rani Jarkas said, “China is now committed to transforming the domestic life sciences industry into a global leader. For example, in recent years, we have seen growing interest from Chinese enterprises and investors to acquire life sciences technologies and products overseas to enhance China’s market position, and the increased desire of Australian life science companies to build a local presence in China. In this regard, Cedrus has competitive advantages. Through facilitating various deals, Cedrus has accumulated a lot of expertise and valuable experience in cross-border transactions and collaborations. We fully understand the potential sensitivity issues, apparent and hidden, involved in life sciences transactions across borders; hence, we can likely prevent companies from entering into unfavorable collaborations long term. In addition, we understand how to protect the companies’ assets such as intellectual properties, monetize their assets and maximize value, coupled with helping them to achieve their financial and business targets while minimizing business risks.”

Cedrus Investments' Chairman Mr. Rani Jarkas Invited to Speak at the 121 Mining Investment Hong Kong Conference

http://www.kuam.com/story/36992615/cedrus-investments-chairman-mr-rani-jarkas-invited-to-speak-at-the-121-mining-investment-hong-kong-conference

Rani Jarkas speaks 11th Mines and Money Asia

https://asia.minesandmoney.com/speakers/rani-jarkas/

王雷（Rani Jarkas）：香港仍将是极具竞争力的全球金融中心 赛德思投资董事长 王雷（Rani Jarkas）

中国国家主席习近平今天抵达香港进行为期三天的行程，期间将出席庆祝香港回归祖国20周年大会暨香港特别行政区第五届政府就职典礼。

“习主席在这个重大时刻莅临出席庆祝活动和就职典礼，并视察香港特别行政区，充分显示中央对香港的重视和支持，”香港特区行政长官梁振英说。

随着中国持续增强其在全球政治经济舞台上的重要性，中央政府驻香港联络办公室主任张晓明评论道：“现在国家有三大发展战略都和香港密切相关，即“一带一路”建设、人民币国际化、粤港澳大湾区城市群规划和建设。

总部位于香港的全球精品投资公司——赛德思投资董事长王雷(Rani Jarkas)表示：“20年来，香港特别行政区在国家的大力支持下，取得多方面的成就。香港保持了并仍将保持是全球金融、货运和贸易中心之一，并且一直被评选为全球最自由经济体以及最具竞争力地区之一。”

Rani Jarkas: China’s outbound M&As surge in both volume and value

In the first half of 2016, the volume of cross-border mergers and acquisitions led by Chinese buyers reached $149.2 billion, exceeding the total volume in 2015. The amount accounted for 23 percent of the total volume of global cross-border M&A, up from 6 percent in the same period last year, according to Tian Guoli, chairman of Bank of China on at the Bank of China - Bloomberg Global M&A Summit.
Smooth financing channels in capital markets and fast-growing financial investors are the main reasons for the significant increase in 2016.
Mature markets such as Europe and North America continued to be the main destinations for Chinese buyers of sophisticated technology, advanced management experience and well-known brands. Asia was also popular among investors because of the Belt and Road Initiative.
Also, for the first time, privately-owned enterprises surpassed state-owned enterprises in transaction value, accounting for half of the total over the first three quarters of 2016.

Rani Jarkas, Chairman of Cedrus Investments, a boutique investment firm with years of experience in Greater China region, said “The expansion from trade finance to acquisition finance will provide a strategic opportunity for development of the Chinese financial sector. It has accelerated the transformation of China’s financial industry.”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. - Rani Jarkas

王雷（Rani Jarkas）：中国对外并购在质和量上均发展迅速

王雷（Rani Jarkas）： 中国银行董事长田国立在中国银行—彭博全球并购峰会上表示，2016年上半年，由中国买家主导的跨境并购达到了1492亿美元，超过了2015年全年总量，占到全球总量的23%，比去年同期增长了6个百分点。

 在资本市场更为便捷的融资渠道和快速增长的金融投资者数量是2016年显著发展的主要原因。

 类似欧洲和北美这样的成熟市场仍然是中国买家获取成熟技术、先进管理经验和知名品牌的热门地区。由于“一带一路”倡议，亚洲也深受投资者欢迎。

 同时，私营企业首次在交易金额上超过国有企业，占到2016前三季度总量的一半。

 精品投资公司赛德思投资董事长王雷在大中华区拥有多年经验，他表示：“从贸易金融向收购金融的扩张将为中国金融领域的发展提供战略机遇，加速中国金融产业的转型。”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. - Rani Jarkas

RANI JARKAS, CHAIRMAN OF CEDRUS INVESTMENTS, WELCOMES MR. RANDY HICE JOINING THE LIFE SCIENCES ADVISORY BOARD

HONG KONG, 23rd August, 2016 – Abbott Informatics’ Manager of Global Strategy, Mr. Randy Hice, joins Cedrus Investments’ (“Cedrus”) Life Sciences Advisory Board.
Randy is recognized worldwide as a leading authority in laboratory informatics, specifically focused on complex, large-scale implementation of Laboratory Information Management Systems (LIMS), Laboratory Information Systems (LIS), Electronic Laboratory Notebook (ELN), and sophisticated Cloud architectures.  He has been working in the field of laboratory automation since 1984, first as a programmer/analyst at Digital Equipment Corporation, then as a Principal with Laboratory Expertise Center.  In 1989, he pioneered Laboratory Workflow Analysis as a methodology for system selection, project planning, harmonization, and system design.  With STARLIMS Corporation purchasing Laboratory Expertise Center in 2008 and STARLIMS being acquired subsequently, he now serves as the Manager of Global Strategy for Abbott Informatics where his focus is on complex business analysis, harmonization, inter-operational platforms, Clinical LIS, and Cloud Computing. He is also responsible for analyzing global market potential, demand and profitability for complex informatics systems.
Randy has developed global laboratory automation and harmonization strategies for leading pharmaceutical, biotechnology, medical device, and Contract Research Organization (CRO) companies, identifying opportunities to share and utilize critical laboratory data across corporate locations in Europe, Asia, and the U.S.
As the manager of the Strategic Consulting group of Abbott Informatics, Randy assumed the visionary role of leading the Cloud Services initiative in which he developed service offerings in Infrastructure as a Service (IaaS) and Software as a Service (SaaS) areas to meet the growing demand for Cloud applications.
Randy is the most published author in the world of laboratory automation and workflow analysis, and has served as the monthly Laboratory Automation editor for the Scientific Computing magazine since 1996.  He has also contributed to American Pharmaceutical Review and American Laboratory.
Cedrus Investments has been investing in and providing financial advisory services to the life sciences industry for over a decade.  In recent years, the firm has been assisting Australian and European life sciences companies to increase their visibility with a broad pool of institutional investors in the Greater China region.  At the same time, Cedrus also helps Chinese biopharmaceutical companies and investors to identify valuable overseas investment opportunities.
Mr. Hice said, “I am delighted to join the Cedrus’ Life Sciences Advisory Board. I look forward to sharing my expertise and experience with the Cedrus’ team to identify and evaluate exciting investment opportunities.”

Mr. Rani Jarkas, Chairman of Cedrus Investments extended his welcome and said, “We are excited to have Mr. Randy Hice joined our Life Sciences Advisory Board.  As a reputable figure in laboratory informatics, Randy is an ideal addition to the board.  His decades of experience and in-depth knowledge will be invaluable to both Cedrus’ direct investments and its investor clients from across the globe.  In addition, Randy’s global connections and business development skills in the industry also solidify Cedrus’ unique position in identifying early opportunities to maximize investment returns.”

Rani Jarkas, the Chairman of Cedrus Investments

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. - Rani Jarkas